Tecan Group AG · SIX:TECN
Tecan — UBS Global Healthcare Conference 2019
21 slides from Tecan's conference presentation, May 21, 2019
Slide 1: UBS Global Healthcare Conference
Tecan Group UBS Global Healthcare Conference DR. ACHIM VON LEOPRECHTING, CEO MAY 21, 2019 NEW YORK CITY
Slide 2: Safe Harbor Statement
Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions of the future and constitute no guarantee whatsoever of future performances. They are subject to risks and uncertainties including, but not limited to, future global economic conditions, excha
Slide 3: Empowering the Century of Biology
Empowering the Century of Biology. v 42 z2 zy 52
Slide 4: Tecan Competencies Empowering the Century of Biology
Tecan Competencies Empowering the Century of Biology FROM DISCOVERY OF NOVEL MEDICATIONS ALL THE WAY TO BETTER DIAGNOSIS OF DISEASES HEALTHCARE USE APPLICATIONS TECAN’S ENABLING COMPETENCIES Better… • Genomics • Applications and Workflows • understand • Protein analysis • Robotics and Automation Can
Slide 5: Empowering Genetic Testing
Empowering Genetic Testing MEDICAL TESTS THAT IDENTIFY CHANGES IN CHROMOSOMES, GENES OR PROTEINS • Molecular genetic tests (or genomic tests) • Non-Invasive Pre-Natal Testing (NIPT) • Chromosomal tests • Liquid biopsies • Biochemical tests • Personalized Precision Medicine © 2018 Genomic Health,; ht
Slide 6: Tecan's Vision Statement
Tecan’s Vision Statement Our vision is to empower every laboratory, every day, around the world with Tecan technology, products and support. We will help to shape the future of automated workflows in life sciences and clinical diagnostics through unrivaled expertise, products and customer support. 6
Slide 7: Introduction
Introduction Tecan Group Berenberg European Conference Pennyhill Park DR. DAVID MARTYR, CEO DECEMBER 6, 2018
Slide 8: Introducing Tecan
Introducing Tecan • Pioneer and global leader in laboratory automation since almost 40 years • Our solutions accelerate, automate and enhance the processes in state-of-the-art diagnostics and life sciences labs • Offering solutions in select application areas: • Immunoassays for specialty diagnostic
Slide 9: Tecan's Products, Business Structure and Markets
Tecan’s Products, Business Structure and Markets •LIFE SCIENCES Life Sciences BUSINESS Business •PARTNERING BUSINESS Partnering Business • Focused on all end-user activities • Focused on all OEM activities • Products marketed under the Tecan brand through • Products sold by partners under their own
Slide 10: Transition from Research to Diagnostics
Transition from Research to Diagnostics TECAN HAS A UNIQUE POSITION TO BRIDGE FROM RESEARCH TO DIAGNOSTICS SETTINGS LIFE SCIENCE RESEARCH LAB DEVELOPED TESTS (LDT) IN-VITRO DIAGNOSTICS Life Sciences Life Sciences Partnering Business Business Business Covering individual steps of a Sample-to-Result S
Slide 11: Growth Drivers & Product Launches
Growth Drivers & Product Launches
Slide 12: Basis for Corporate Strategy: Market Structure
Basis for Corporate Strategy: Market Structure LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS CAGR +3-5% +3-5% STRATEGIC PILLARS >55 BN USD >60 BN USD 1 Scale & capability 2 Build additional pillars and complete portfolio 3 Offer solutions in selected areas Life Sciences Partnering Business Business 12
Slide 13: Life Sciences Business: DreamPrep
DreamPrep™ the latest Fluent dream LIFE SCIENCES BUSINESS TECAN’S FASTEST KITS ON TECAN’S FASTEST PLATFORM • Combining innovative NGS kits for library preparation and QC for research customers with Tecan automation • Library prep is the most critical step prior to sequencing • Acquisition of NuGEN (
Slide 14: Life Sciences Business: Spark Next Generation Reader Platform
Spark Next Generation Reader Platform LIFE SCIENCES BUSINESS NEW EXCITING VARIANTS OF THE SPARK READER ALREADY ON THE MARKET COMING SOON… Greater flexibility, increased speed and productivity New high-end advanced imaging product • Industry leading sensitivity and speed • Integrated microscopy for a
Slide 15: Partner of Choice to the IVD Industry
Partner of Choice to the IVD Industry PARTNERING BUSINESS 30+ ACTIVE INSTRUMENT ACCOUNTS, MULTIPLE DEVELOPMENTS IN PROGRESS IN REGULAR INSTRUMENTS UNDER INSTRUMENT SUPPLY PHASE RAMPING UP DEVELOPMENT PIPELINE 35+ different instruments supplied 5+ projects under 25+ concrete concepts in development d
Slide 16: Financials and Outlook
¥ Financials and O I l ] I I ] I I I TECAN
Slide 17: Financial Summary
Financial Summary SALES DEVELOPMENT OPERATING PROFIT (EBITDA) 593.8 600 120 548.6 110.3 550 110 104.6 506.2 500 100 CHF (mio) 440.3 89.0 CHF (mio) 450 90 391.1 388.3 399.5 83.4 400 80 350 65.1 67.5 70 63.0 300 60 250 50 2012 2013 2014 2015 2016 2017 2018 2012 2013 2014 2015 2016 2017 2018 OPERATING
Slide 18: Financial Outlook for 2019
Financial Outlook for 2019 SALES DEVELOPMENT SALES OUTLOOK 700 Growth in MSD to •Forecast for growth in local currencies in the mid- to 650 HSD range in LC1 high single-digit percentage range 600 593.8 •Potential additional acquisitions not taken into account CHF (mio) 550 548.6 506.2 500 450 440.3
Slide 19: June 6, 2019
June 6, 2019 Maennedorf, CH (webcasted) @TECAN.
Slide 20: Slide 20
Slide 21: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif